Leerink Partnrs Weighs in on AnaptysBio, Inc.’s Q1 2024 Earnings (NASDAQ:ANAB)

AnaptysBio, Inc. (NASDAQ:ANAB) – Leerink Partnrs issued their Q1 2024 earnings estimates for shares of AnaptysBio in a research report issued to clients and investors on Tuesday, April 16th. Leerink Partnrs analyst D. Risinger forecasts that the biotechnology company will earn ($1.41) per share for the quarter. Leerink Partnrs has a “Outperform” rating on the stock. The consensus estimate for AnaptysBio’s current full-year earnings is ($6.25) per share. Leerink Partnrs also issued estimates for AnaptysBio’s Q2 2024 earnings at ($1.44) EPS, Q3 2024 earnings at ($1.45) EPS, Q4 2024 earnings at ($1.42) EPS, FY2024 earnings at ($5.71) EPS, Q1 2025 earnings at ($1.91) EPS, Q2 2025 earnings at ($1.86) EPS, Q3 2025 earnings at ($1.85) EPS, Q4 2025 earnings at ($1.14) EPS, FY2025 earnings at ($6.37) EPS, FY2026 earnings at ($4.82) EPS, FY2027 earnings at ($3.95) EPS and FY2028 earnings at ($3.39) EPS.

A number of other equities research analysts also recently weighed in on ANAB. Wedbush upgraded AnaptysBio from a “neutral” rating to an “outperform” rating and lifted their target price for the stock from $20.00 to $34.00 in a report on Tuesday, March 12th. Piper Sandler started coverage on shares of AnaptysBio in a research note on Friday, February 16th. They set an “overweight” rating and a $80.00 target price on the stock. SVB Leerink started coverage on shares of AnaptysBio in a report on Tuesday. They set an “outperform” rating and a $47.00 price objective on the stock. Wells Fargo & Company started coverage on AnaptysBio in a report on Thursday, April 11th. They issued an “overweight” rating and a $56.00 price target on the stock. Finally, BTIG Research assumed coverage on AnaptysBio in a report on Monday, February 26th. They issued a “buy” rating and a $55.00 target price on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $46.22.

AnaptysBio Price Performance

Shares of NASDAQ:ANAB opened at $19.83 on Thursday. AnaptysBio has a 1 year low of $13.36 and a 1 year high of $27.50. The business’s 50-day moving average is $23.31 and its 200-day moving average is $20.54. The company has a market capitalization of $530.65 million, a price-to-earnings ratio of -3.26 and a beta of -0.30.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Monday, March 11th. The biotechnology company reported ($1.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.74) by $0.15. AnaptysBio had a negative net margin of 953.66% and a negative return on equity of 119.42%. The business had revenue of $9.01 million for the quarter, compared to analyst estimates of $3.28 million.

Insider Buying and Selling at AnaptysBio

In related news, CEO Daniel Faga sold 145,940 shares of the business’s stock in a transaction dated Friday, March 22nd. The shares were sold at an average price of $22.78, for a total transaction of $3,324,513.20. Following the transaction, the chief executive officer now directly owns 752,087 shares in the company, valued at $17,132,541.86. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, CFO Dennis Mulroy sold 3,065 shares of the stock in a transaction that occurred on Tuesday, January 30th. The stock was sold at an average price of $23.63, for a total transaction of $72,425.95. Following the completion of the sale, the chief financial officer now directly owns 964 shares of the company’s stock, valued at $22,779.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Daniel Faga sold 145,940 shares of AnaptysBio stock in a transaction on Friday, March 22nd. The stock was sold at an average price of $22.78, for a total value of $3,324,513.20. Following the sale, the chief executive officer now owns 752,087 shares in the company, valued at $17,132,541.86. The disclosure for this sale can be found here. In the last three months, insiders have sold 157,005 shares of company stock worth $3,586,199. Corporate insiders own 35.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ANAB. Hudson Bay Capital Management LP grew its position in shares of AnaptysBio by 100.0% during the 3rd quarter. Hudson Bay Capital Management LP now owns 100,000 shares of the biotechnology company’s stock valued at $1,796,000 after acquiring an additional 50,000 shares during the period. China Universal Asset Management Co. Ltd. grew its position in shares of AnaptysBio by 350.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,072 shares of the biotechnology company’s stock valued at $66,000 after purchasing an additional 2,390 shares in the last quarter. Jacobs Levy Equity Management Inc. lifted its holdings in AnaptysBio by 4.1% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 206,785 shares of the biotechnology company’s stock worth $3,714,000 after purchasing an additional 8,064 shares in the last quarter. Victory Capital Management Inc. purchased a new position in AnaptysBio during the third quarter valued at approximately $785,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of AnaptysBio by 134.4% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,896 shares of the biotechnology company’s stock valued at $106,000 after purchasing an additional 3,381 shares in the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.